Regulatory News:

BONE THERAPEUTICS, the bone cell therapy company addressing high
unmet medical needs in the field of bone fracture repair and bone
fracture prevention, today announces that it has established its US
based subsidiary, Bone Therapeutics USA Inc. in Boston, Massachusetts,
in line with its strategy as outlined at the time of its recent initial
public offering. The establishment of the US headquarters is the first
step for the Company to move forward its US clinical trials programme.

This new subsidiary of Bone Therapeutics is situated in Kendall Square,
Cambridge. The world?s ten largest biopharma companies have a presence
in Massachusetts, making it an ideal location for scientific and
technological innovation and ideally suited for Bone Therapeutics? first
US foothold.

The creation of this affiliate is the first milestone in a process that
will lead to the initiation of Bone Therapeutics? clinical trials for
fracture repair and osteonecrosis in the US.

Enrico Bastianelli, CEO of Bone Therapeutics, commented: ?The
creation of a subsidiary in the US is an important step forward in our
strategy as set out at the time of the IPO. This further strengthens the
international reach of our innovative pipeline of bone cell therapy
products. We are very excited to become part of the biotechnology
cluster in Cambridge and believe this prime location will prove to be
extremely beneficial to the Company as we move our clinical development
forward in this important market.?

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in
the development of cell therapy products intended for bone fracture
repair and fracture prevention. The current standard-of-care in this
field involves major surgeries and long recovery periods. To overcome
these problems, Bone Therapeutics is developing a range of innovative
regenerative products containing osteoblastic/bone-forming cells,
administrable via a minimally invasive percutaneous technique; a unique
proposition in the market.

PREOB®, Bone Therapeutics? autologous bone
cell product, is currently in pivotal Phase IIB/III clinical studies for
two indications: osteonecrosis and non-union fractures, and in Phase II
for severe osteoporosis. ALLOB
®, its allogeneic
?off-the-shelf? bone cell product, is in Phase II for the treatment of
delayed-union fractures and lumbar fusion for degenerative disease of
the spine. The Company also runs preclinical research programs and
develops novel product candidates.

Founded in 2006, Bone Therapeutics is headquartered in Gosselies
(South of Brussels, Belgium). Bone Therapeutics? regenerative products
are manufactured to the highest GMP standards and are protected by a
rich IP estate covering 9 patent families. Further information is
available at

Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect the Company or, as appropriate, the
Company directors? current expectations and projections about future
events. By their nature, forward-looking statements involve a number of
risks, uncertainties and assumptions that could cause actual results or
events to differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties and assumptions
could adversely affect the outcome and financial effects of the plans
and events described herein. A multitude of factors including, but not
limited to, changes in demand, competition and technology, can cause
actual events, performance or results to differ significantly from any
anticipated development. Forward looking statements contained in this
press release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in the
future. As a result, the Company expressly disclaims any obligation or
undertaking to release any update or revisions to any forward-looking
statements in this press release as a result of any change in
expectations or any change in events, conditions, assumptions or
circumstances on which these forward-looking statements are based.
Neither the Company nor its advisers or representatives nor any of its
subsidiary undertakings or any such person?s officers or employees
guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking statements
contained in this press release or the actual occurrence of the
forecasted developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.

Print Friendly, PDF & Email

Bone Therapeutics Establishes US Subsidiary